OptimizeRx Corporation Appoints Stephen Silvestro as Chief Executive Officer
OptimizeRx (Nasdaq: OPRX) has appointed Steve Silvestro as its new Chief Executive Officer, effective March 10, 2025. Silvestro, who has been with the company since 2019, brings over 20 years of experience in health technology and services.
Previously serving as Chief Commercial Officer, President, and interim CEO, Silvestro was unanimously selected by the independent Directors following a rigorous search process. During his tenure at OptimizeRx, he has been important in transforming the company from a single-solution digital marketing provider to an industry leader with omnichannel capabilities.
The new CEO's strategic priorities include:
- Focusing on operational excellence and customer satisfaction
- Expanding value proposition with pharmaceutical companies
- Increasing recurring revenue model
- Driving towards becoming a Rule of 40 company
- Creating new opportunities for profitable revenue growth
OptimizeRx (Nasdaq: OPRX) ha nominato Steve Silvestro come nuovo Amministratore Delegato, con effetto dal 10 marzo 2025. Silvestro, che è con l'azienda dal 2019, porta con sé oltre 20 anni di esperienza nel settore della tecnologia e dei servizi sanitari.
In precedenza, ha ricoperto i ruoli di Chief Commercial Officer, Presidente e CEO ad interim; Silvestro è stato scelto all'unanimità dai Direttori indipendenti dopo un rigoroso processo di selezione. Durante il suo mandato in OptimizeRx, è stato fondamentale nel trasformare l'azienda da fornitore di marketing digitale a soluzione unica a leader di settore con capacità omnichannel.
Le priorità strategiche del nuovo CEO includono:
- Focalizzarsi sull'eccellenza operativa e sulla soddisfazione del cliente
- Espandere la proposta di valore con le aziende farmaceutiche
- Aumentare il modello di entrate ricorrenti
- Orientarsi verso la creazione di un'azienda conforme alla Regola del 40
- Creare nuove opportunità per una crescita redditizia delle entrate
OptimizeRx (Nasdaq: OPRX) ha nombrado a Steve Silvestro como su nuevo Director Ejecutivo, con efecto a partir del 10 de marzo de 2025. Silvestro, que ha estado en la empresa desde 2019, aporta más de 20 años de experiencia en tecnología y servicios de salud.
Anteriormente ocupó los cargos de Director Comercial, Presidente y CEO interino; Silvestro fue seleccionado unánimemente por los Directores independientes tras un riguroso proceso de búsqueda. Durante su tiempo en OptimizeRx, ha sido fundamental en la transformación de la empresa de proveedor de marketing digital de solución única a líder de la industria con capacidades omnicanal.
Las prioridades estratégicas del nuevo CEO incluyen:
- Enfocarse en la excelencia operativa y la satisfacción del cliente
- Ampliar la propuesta de valor con las compañías farmacéuticas
- Aumentar el modelo de ingresos recurrentes
- Avanzar hacia convertirse en una empresa Regla del 40
- Crear nuevas oportunidades para un crecimiento de ingresos rentable
OptimizeRx (Nasdaq: OPRX)는 Steve Silvestro를 새로운 CEO로 임명하며, 2025년 3월 10일부터 효력이 발생합니다. Silvestro는 2019년부터 회사에 재직해 왔으며, 건강 기술 및 서비스 분야에서 20년 이상의 경험을 보유하고 있습니다.
이전에는 상업 책임자, 사장 및 임시 CEO로 재직하였으며, Silvestro는 철저한 검색 프로세스 후 독립 이사들에 의해 만장일치로 선택되었습니다. OptimizeRx에서의 그의 재임 기간 동안, 그는 회사를 단일 솔루션 디지털 마케팅 제공업체에서 옴니채널 기능을 갖춘 업계 리더로 변모시키는 데 중요한 역할을 했습니다.
새로운 CEO의 전략적 우선사항은 다음과 같습니다:
- 운영 우수성과 고객 만족에 집중
- 제약 회사와의 가치 제안 확대
- 정기 수익 모델 증가
- Rule of 40 회사로 성장하기 위한 추진
- 수익성 있는 수익 성장 기회 창출
OptimizeRx (Nasdaq: OPRX) a nommé Steve Silvestro comme nouveau Directeur Général, prenant effet le 10 mars 2025. Silvestro, qui est avec l'entreprise depuis 2019, apporte plus de 20 ans d'expérience dans la technologie et les services de santé.
Auparavant, il a occupé les postes de Directeur Commercial, Président et CEO par intérim ; Silvestro a été choisi à l'unanimité par les Directeurs indépendants après un processus de recherche rigoureux. Pendant son mandat chez OptimizeRx, il a été essentiel dans la transformation de l'entreprise d'un fournisseur de marketing numérique à solution unique en leader du secteur avec des capacités omnicanal.
Les priorités stratégiques du nouveau CEO incluent:
- Se concentrer sur l'excellence opérationnelle et la satisfaction client
- Élargir la proposition de valeur avec les entreprises pharmaceutiques
- Augmenter le modèle de revenus récurrents
- Travailler à devenir une entreprise conforme à la règle des 40
- Créer de nouvelles opportunités de croissance des revenus rentables
OptimizeRx (Nasdaq: OPRX) hat Steve Silvestro zum neuen Chief Executive Officer ernannt, der am 10. März 2025 in Kraft tritt. Silvestro, der seit 2019 im Unternehmen ist, bringt über 20 Jahre Erfahrung im Bereich Gesundheitstechnologie und Dienstleistungen mit.
Vorher war er als Chief Commercial Officer, Präsident und interimistischer CEO tätig; Silvestro wurde einstimmig von den unabhängigen Direktoren nach einem rigorosen Auswahlprozess ausgewählt. Während seiner Amtszeit bei OptimizeRx war er entscheidend daran beteiligt, das Unternehmen von einem Anbieter für digitale Marketinglösungen zu einem Branchenführer mit Omnichannel-Fähigkeiten zu transformieren.
Die strategischen Prioritäten des neuen CEOs umfassen:
- Fokus auf operative Exzellenz und Kundenzufriedenheit
- Erweiterung des Wertangebots mit Pharmaunternehmen
- Steigerung des wiederkehrenden Einnahmemodells
- Streben, ein Rule of 40-Unternehmen zu werden
- Schaffung neuer Chancen für profitables Umsatzwachstum
- Unanimous board approval indicates strong leadership alignment
- New CEO brings 6 years of internal company experience and proven track record
- Clear strategic focus on profitable growth and recurring revenue model
- Successful transformation from single-solution to omnichannel capabilities under Silvestro's leadership
- Leadership transition period may cause temporary operational adjustments
Silvestro has a demonstrated record of accelerating revenue growth, expanding brand relevance, and building a market-leading team
WALTHAM, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced it has appointed Steve Silvestro as the Company’s new Chief Executive Officer, effective March 10, 2025.
Mr. Silvestro brings to OptimizeRx more than 20 years of experience in building and managing health technology and services companies, and has served as an executive at OptimizeRx since joining the Company in 2019. His career includes strategic development, sales leadership, technology and product innovation, and M&A within a variety of leadership roles.
"The Board of Directors completed a rigorous search and selection process for a new CEO that was conducted by the Company’s independent Directors with the assistance of a leading executive search firm and is very pleased to announce that it was the unanimous decision of the independent Directors to appoint Steve Silvestro as the next OptimizeRx CEO," said Lynn Vos, Chairperson of OptimizeRx's Board of Directors. "Since starting at OptimizeRx six years ago as the Chief Commercial Officer, and more recently serving as President and interim CEO, Steve has been instrumental in growing the Company’s brand relevance within the life sciences industry and transforming the Company from an early stage, single solution in the digital marketing space to an industry mainstay with omnichannel capabilities. At this pivotal time in OptimizeRx’s history, we are confident that Steve is the right transformative leader to drive OptimizeRx into its next phase of profitable revenue growth and shareholder value creation."
"I am honored to have the Board's trust and to have the opportunity to lead the next phase of OptimizeRx’s growth and transformation. We will continue to differentiate ourselves within the market through our technology and by developing more meaningful strategic partnerships with our customers. Now more than ever, we will be laser-focused on operational excellence while ensuring we delight our customers and forge stronger relationships with valued business partners," added Steve Silvestro. “Since the time I was asked to take the helm in December, we have completed an extensive strategic review of the Company’s business processes, operations, and opportunities for shareholder value creation. I look forward to collaborating with our Board, team members, strategic partners, and customers as we continue the Company’s growth, focusing very closely on customer centricity and delight, continuing to expand our value proposition with pharma, increasing our re-occurring revenue model while driving to become a Rule of 40 company, and unlocking new opportunities for profitable revenue growth and shareholder value creation.”
Mr. Silvestro’s Bio
Mr. Silvestro was appointed the Chief Executive Officer in March 2025. He joined the Company as Chief Commercial Officer in April 2019, and has since served as President and, most recently, as the Company’s interim CEO. Prior to joining the Company, Mr. Silvestro held leadership positions at various companies including CCH® Tagetik, a Wolters Kluwer company that provides corporate performance management software solutions for planning, consolidation and reporting, Prognos Health, Inc., a healthcare data and analytics company, Decision Resources Group, a multi-national corporation that provides high value global data solutions, analytics and consulting services to pharmaceutical, biotech, medical device, healthcare provider and payer companies. Mr. Silvestro received his Master of Liberal Arts in Business Management from Harvard University and his Bachelor of Arts in Italian and Business Management from Brigham Young University.
About OptimizeRx
OptimizeRx is a leading healthcare technology company that’s redefining how life science brands connect with patients and healthcare providers. Our platform combines innovative AI-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. By bridging the gap between HCP and DTC strategies, we empower brands to create synchronized marketing solutions that drive faster treatment decisions and improved patient outcomes.
Our commitment to privacy-safe, patient-centric technology ensures that every interaction is designed to make a meaningful impact, delivering life-changing therapies to the right patients at the right time. Headquartered in Waltham, Massachusetts, OptimizeRx partners with some of the world’s leading pharmaceutical and life sciences companies to transform the healthcare landscape and create a healthier future for all.
Important Cautions Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipates", "believes", "estimates", "expects", "forecasts", "intends", "plans", "projects", "targets", "designed", "could", "may", "should", "will" or other similar words and expressions are intended to identify these forward-looking statements. All statements in this press release that reflect the Company's expectations, assumptions, projections, beliefs or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to the future contributions of Mr. Silvestro to the Company, the Company's growth and transformation, plans for profitable revenue growth, plans for creating, enhancing and unlocking shareholder value, plans for differentiating the Company through its technology, plans for developing more meaningful strategic partnerships with the Company’s customers, plans for expanding the Company’s value proposition with pharma, plans for increasing the Company’s re-occurring revenue while driving to become a Rule of 40 company and unlocking new opportunities for profitable revenue growth, plans for expanding relationships with customers and strategic partners, plans for forging stronger relationships with valued business partners, other business plans and operating and financial performance objectives, and other statements relating to future performance, plans, and expectations. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company’s current expectations and involve assumptions regarding the Company's business, the economy, and other future conditions that may never materialize or may prove to be incorrect. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties including, but not limited to, the effect of government regulation, seasonal trends, dependence on a concentrated group of customers, cybersecurity incidents that could disrupt operations, the ability to keep pace with growing and evolving technology, the ability to maintain contracts with electronic prescription platforms and electronic health records networks, competition, and other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, and in other filings the Company has made and may make with the SEC in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.
OptimizeRx Contact
Andy D’Silva, SVP Corporate Finance
adsilva@optimizerx.com
Investor Relations Contact
Sandya von der Weid
LifeSci Advisors, LLC
svonderweid@lifesciadvisors.com
FAQ
When will Steve Silvestro assume the CEO position at OptimizeRx (OPRX)?
What is Steve Silvestro's background and experience at OptimizeRx (OPRX)?
What are the main strategic priorities announced by OptimizeRx's new CEO?
How was Steve Silvestro selected as the new CEO of OptimizeRx (OPRX)?
